Session » SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III
- 10:30AM-12:30PM
-
Abstract Number: 2331
Assessment of the Likelihood of Joint Inflammation Recurrence in Previously Affected Joints During Psoriatic Arthritis Disease Course
- 10:30AM-12:30PM
-
Abstract Number: 2334
Characteristics of Patients with Psoriatic Arthritis Presenting with Axial Involvement: Results of a Prospective International Multicenter Study (AXIS)
- 10:30AM-12:30PM
-
Abstract Number: 2317
Chronic Kidney Disease in Patients with Psoriatic Arthritis: A Cohort Study
- 10:30AM-12:30PM
-
Abstract Number: 2326
Development and Evaluation of a Machine Learning Model for the Early Identification of Psoriatic Arthritis
- 10:30AM-12:30PM
-
Abstract Number: 2327
Differential Quantitative Profile of Myeloid Derived Suppressor Cells and Monocyte Subsets Relate to Clinical Phenotype and Disease Activity in Psoriatic Arthritis Patients
- 10:30AM-12:30PM
-
Abstract Number: 2340
Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Diagnosis Rates, Referral Pathways, and Educational Value of Screening
- 10:30AM-12:30PM
-
Abstract Number: 2328
Do Patients That Develop PsA Before Psoriasis Have Different Disease Outcomes?
- 10:30AM-12:30PM
-
Abstract Number: 2318
Does the Time Interval Between the Onset of Psoriasis and Psoriatic Arthritis Impact Disease Presentation and Outcomes?
- 10:30AM-12:30PM
-
Abstract Number: 2315
Exploring Antibodies in Psoriatic Arthritis: A Novel Autoimmune Biomarker Discovered
- 10:30AM-12:30PM
-
Abstract Number: 2324
Familial Aggregation in Psoriatic Arthritis: Phenotypic Differences in Patients with and Without First-degree Relatives with Psoriatic Disease
- 10:30AM-12:30PM
-
Abstract Number: 2329
Feasibility of a Streamlined Approach for Psoriatic Arthritis Screening and Symptom Assessment
- 10:30AM-12:30PM
-
Abstract Number: 2316
Gene Expression Profile Is Different Between Men and Women in Psoriatic Disease
- 10:30AM-12:30PM
-
Abstract Number: 2335
Hand Function and Development of Psoriatic Arthritis in Skin Psoriasis Patients, a Prospective Cohort Study
- 10:30AM-12:30PM
-
Abstract Number: 2311
Higher Rates of Psoriatic Arthritis in Patients with Calcium Pyrophosphate Deposition Disease Than Controls: A Retrospective Cohort Study in US Veterans
- 10:30AM-12:30PM
-
Abstract Number: 2339
Increased Risk of Psoriatic Arthritis in Patients with Familial Mediterranean Fever: A Population-Based Cohort Study
- 10:30AM-12:30PM
-
Abstract Number: 2319
Investigating the Association of Serum Metabolites with Psoriatic Arthritis Musculoskeletal Disease Patterns
- 10:30AM-12:30PM
-
Abstract Number: 2330
Mental Health, Sex, and Comorbidities as Determinants of Recalcitrant PsA
- 10:30AM-12:30PM
-
Abstract Number: 2320
Nailfold Videocapillaroscopy Findings in Patients with Psoriatic Disease: Is There a Distinctive Psoriatic Pattern?
- 10:30AM-12:30PM
-
Abstract Number: 2312
National Prevalence of Psoriatic Arthritis in the United States: Data from National Health and Nutrition Examination Survey [NHANES]
- 10:30AM-12:30PM
-
Abstract Number: 2337
Patient Characteristics and Outcomes of Emergency Visits in Psoriatic Arthritis: Results from the U.S. Nationwide Emergency Department Sample (NEDS)
- 10:30AM-12:30PM
-
Abstract Number: 2336
Patients with Psoriasis with a Positive Psoriasis Epidemiology Screening Tool (PEST): Similarities and Differences Compared to PsA and Patients with Psoriasis and a Negative PEST
- 10:30AM-12:30PM
-
Abstract Number: 2325
Predictors of Treatment Response and Continuation in Patients with Psoriatic Arthritis Initiating Secukinumab – Results from the EuroSpA Collaboration
- 10:30AM-12:30PM
-
Abstract Number: 2322
Predictors of Work Impairment and Absence Amongst People with Psoriatic Arthritis (PsA) – Evidence from the British Society for Rheumatology PsA Register (BSR-PsA)
- 10:30AM-12:30PM
-
Abstract Number: 2321
Prevalence and Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease
- 10:30AM-12:30PM
-
Abstract Number: 2332
PsAID12 Thresholds Defining Disease Impact Severity in Psoriatic Arthritis Developed in an Observational Setting Showed Higher Sensitivity but Lower Specificity Than Those Developed in a Randomized Controlled Trial Setting
- 10:30AM-12:30PM
-
Abstract Number: 2313
Race and Ethnicity as Predictors of Diagnostic Delay in Psoriatic Arthritis and Axial Spondyloarthritis
- 10:30AM-12:30PM
-
Abstract Number: 2314
Serum Calprotectin (S100A8/9) and Complement Factor C3 as Potential Inflammatory Markers in Obese and “CRP Negative” Early PsA Patients: Data from a Multicenter METAPSA Cohort
- 10:30AM-12:30PM
-
Abstract Number: 2323
The Effect of Biologic Therapies on Serum Metabolic Biomarkers in Patients with Psoriatic Arthritis
- 10:30AM-12:30PM
-
Abstract Number: 2338
TNF Inhibitor Therapy Increases Absolute Lymphocyte Count Which Is Associated with Lower Mortality in Patients with Psoriatic Arthritis
- 10:30AM-12:30PM
-
Abstract Number: 2333
Unveiling New Molecular Signatures in Psoriatic Arthritis Using Comprehensive Proteomic Analysis of Peripheral Mononuclear Cells